Valion Bio, Inc. fired its General Counsel, Melinda Lackey, and is having its drug Entolimod reviewed.

VBIO · Valion Bio, Inc.

The AI's read

The study may provide information about Entolimod, but the filing gives no findings or evidence of patient benefit. The general counsel's departure and a severance payment are reported, with no sign of a wider management change. These facts do not clearly change Valion Bio's outlook.